Clinical Trial Search

Primary: Susceptability Changes in Streptococcus Pneumoniae Distal to the Site of Instillation — 0; 0; 0; 0 Percent of resistant isolates

Primary: Clinical Cure Rate — 37; 31; 27; 33 Participants — p=0.0137

Primary: Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 5 — 111; 0; 95 Participants — p=0.127

Primary: Exploratory Outcomes From Digital Photography — 17; 7 Participants

Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9) — 37; 20 Participants

Primary: The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3 — 48; 29 participants

Primary: Clinical Resolution — 167; 147 Participants

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7 — 78.6; 84.4 Percentage of Patients

Primary: Number of Subjects With Clinical Resolution of Bacterial Conjunctivitis — 71; 59 Participants — p=0.2219

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 — 74.9; 65.2 Percentage of Patients

Primary: Clinical Resolution of Baseline Bacterial Conjunctivitis — 90; 63 Participants

Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 — 51.8; 41.3 Percentage of Patients

Primary: Change From Baseline Bacterial Culture — 30; 16; 26; 29 cultures — p=0.002

Primary: Clinical Cure at the Day 4 (EOT)/Exit Visit — 62.5; 50.6 percentage of subjects

Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants

Primary: Total Number of Participants With Negative Chlamydia Direct Fluorescent Antibody (DFA) Test Results After Oral Azithromycin Treatments — 27 participants

Primary: Complete Clinical Resolution — 9; 0 Participants

Primary: Number of Participants With Normal Physical Examination of the Eye — 49; 37 participants

Primary: Percent Change From Peak Viral Load — 1.9; 13.2 Percent of peak Viral Load — p=0.02

Primary: Clinical Resolution — 89; 62 eyes

Primary: Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days — 18; 28 Participants

Primary: Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population — -11.63; -12.41 Scores on a scale

Primary: Improvement in Signs and Symptoms of Blepharitis — 15; 15 participants

Primary: Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4) — 100.0; 94.4 Percent of patients

Primary: Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1 — 2.573; 2.500; 1.217; 2.647 units on a scale

Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale

Primary: Change in Physician-rated Scale of NLDO From Baseline to Follow-Up Visit at Week 8 or From Baseline to Time of Treatment Failure, if Earlier. — 7; 10; 1; 1 participants

Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects

Primary: Change of Blepharitis Symptoms Score — 1.8; 2.8 score — p=0.03

Primary: Clinical Cure Rate — 85.4; 81.4 percentage of participants